Related Experiment Video
Updated: Aug 11, 2026
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
[Treatment of patients with B-small cell lymphoma using R-CHOP protocol]
Abstract:
Non-Hodgkin's lymphoma is one of the most challenging problems in modern oncology. Creation of drugs inhibiting specifically intracellular signal tracks which being activated in its turn lead to oncogenes hyperexpression and inactivating other genes responsible for suppression of oncogenes, leading eventually to a cell's constant proliferation. This method is a new approach for cancer treatment. Nowadays homogeneous antibodies are widely used against superficial lymphocyte antigens. Rituximab is an anti-CD20 antibody fixed on the surface of malignant cells of most B-small cell lymphomas. In the department of systematic tumors at the institute of oncology of Medical Academy of Sciences a patient with large diffuse B-cell lymphomas had received Rituximab treatment. After the treatment, laboratory data and clinical investigation of the patient showed no signs of the disease. The patient was under observation at the institute of oncology of Medical Academy of Sciences over one year and found clinically, and according to its laboratory data, in a stable remission state.
Insights
Rituximab, an anti-CD20 antibody, effectively treated a patient with large diffuse B-cell lymphoma. The patient achieved a stable remission for over one year, showing no signs of the disease.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Non-Hodgkin's lymphoma presents significant challenges in oncology.
- Targeting intracellular signal pathways offers a novel cancer treatment approach.
- Homogeneous antibodies against lymphocyte antigens are utilized in therapy.
Observation:
- Rituximab, an anti-CD20 antibody, targets malignant B-cells in lymphomas.
- A patient with large diffuse B-cell lymphoma received Rituximab treatment.
- The patient was monitored for over one year post-treatment.
Findings:
- The patient exhibited no signs of disease after Rituximab treatment.
- Laboratory data and clinical investigations confirmed disease absence.
- A stable remission state was maintained for over twelve months.
Implications:
- Rituximab demonstrates efficacy in treating large diffuse B-cell lymphoma.
- Targeted antibody therapy shows promise for B-cell malignancies.
- Successful long-term remission suggests potential for durable treatment outcomes.
